Professor Erik Stroes considers current understanding of the potential of apoCIII and ANGPTL3 inhibition for reducing triglycerides and remnants, and accompanying effects on LDL cholesterol, apoB and HDL cholesterol, and discusses recent data and ongoing research, as well as possible future benefits of new therapies in terms of cardiovascular risk and pancreatitis.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
